Primary breast lymphoma

Extranodal Lymphomas: Pathology and Management

Volumn , Issue , 2008, Pages 168-172

  Martinelli, Giovanni ^a   Ryan, Gail ^b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 62949091533     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (30)

1. Abbondanzo SL, Seidman JD, Lefkowitz M, et al. Primary diffuse large B-cell lymphoma of the breast. A clinicopathologic study of 31 cases. Pathol Res Pract 1996; 192(1): 37-43.
2. Giardini R, Piccolo C, Rilke F. Primary non-Hodgkin’s lymphomas of the female breast. Cancer 1992; 69(3): 725-35.
3. Wiseman C, Liao KT. Primary lymphoma of the breast. Cancer 1972; 29: 1705-12.
4. Kuper-Hommel MJ, Snijder S, Janssen-Heijnen ML, et al. Treatment and survival of 38 female breast lymphomas:a population-based study with clinical and pathological review. Ann Hematol 2003; 82(7): 397-404.
5. Vignot S, Ledoussal V, Nodiot P, et al. Non-Hodgkin’s lymphoma of the breast: a report of 19 cases and a review of the literature. Clin Lymphoma 2005; 6(1): 37-42.
6. Lyons JA, Myles J, Pohlman B, et al. Treatment and progress of primary breast lymphoma: a review of 13 cases. Am J Clin Oncol 2000; 23: 334-6.
7. Wong WW, Schild SF, Halyard MY, et al. Primary non-Hodgkin lymphoma of the breast: the Mayo Clinic experience. J Surg Oncol 2002; 23: 334-6.
8. Ryan GF, Roos DR, Seymour JF. Primary non-Hodgkin’s lymphoma of the breast: retrospective analysis of prognosis and patterns of failure in two Australian centers. Clin Lymphoma Myeloma 2006; 6: 337-41.
9. Ryan G, Martinelli G, Kuper-Hommel M, et al. Primary diffuse large B-cell lymphoma of the breast:prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol 2008; 19(2): 233-41.
10. Aviles A, Delgado S, Nambo MJ, et al. Primary breast lymphoma: results of a controlled clinical trial. Oncology 2005; 69: 256-60.
11. Hugh JC, Jackson FI, Hanson JP, et al. Primary breast lymphoma: an immunohistologic study of 20 new cases. Cancer 1990; 66: 2602.
12. Bobrow LG, Richards MA, Haperfield LC, et al. Breast lymphomas: a clinical pathologic review. Hum Pathol 1982; 24: 274.
13. Liberman L, Giess CS, Dershaw DD, et al. Non Hodgkin lymphoma of the breast: imaging characteristics and correlation with histopathologic findings. Radiology 1994; 192: 157-60.
14. Liberman L, Mason G, Morris EA, et al. Does size matter? Positive predictive value of MRI-detected breast lesions as a function of lesion size. AJR Am J Roentgenol 2006; 186: 426-30.
15. Gasparini M, Bombardieri E, Castellani M, et al. Gallium-67 scintigraphy evaluation of therapy in non-Hodgkin’s lymphoma. J Nucl Med 1998; 39: 1586-90.
16. Delbeke D. Oncological applications of FDG PET imaging: brain tumors, colorectal cancer lymphoma and melanoma. J Nucl Med 1999; 40: 591-603.
17. Levine PH, Zamuco R, Yee HT. Role of fine-needle aspiration cytology in breast lymphoma. Diagn Cytopathol 2004; 30(5): 332-40.
18. Jackson FI, Lalani ZH. Breast lymphoma: radiologic imaging and clinical appearances. Can Assoc Radiol J 1991; 42(1): 48-54.
19. Kiresi DA, Kivrak AS, Ecirli S, et al. Secondary breast, pancreatic, and renal involvement with non-Hodgkin’s lymphoma. Imaging findings. Breast 2006; 15: 106-10.
20. Demirkazik FB. MR imaging features of breast lymphoma. Eur J Radiol 2002; 42(1): 62-4.
21. Morrow M, Freedman G, Darnell A, et al. A clinical oncology perspective on the use of breast MR. Magn Reson Imaging Clin N Am 2006; 14(3): 363-78.
22. Morrow M, Freedman G, Darnell A, et al. Primary lymphoma of the breast: MR imaging features. A case report. J Magn Res Imaging 1999; 17: 199-202.
23. Horning SG, Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern Cooperative Oncology Group Study 1484. J Clin Oncol 2004; 22: 3032-8.
24. Miller T, Dahlberg S, Cassady J, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med 1998; 339: 21-6.
25. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma:a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-91.
26. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:a study by the Groupe d’Etude des Lym - phomes de l’Adulte. J Clin Oncol 2005; 23(18): 4117-26.
27. Lopez-Guillermo A, Colomo L, Jimenez M, et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to nodal or extranodal primary origin. J Clin Oncol 2005; 23: 2797-804.
28. Mattia AR, Ferri JA, Harris NL. Breast lymphoma. A B-cell spectrum including low-grade B-cell lymphoma of mucosa associated lymphoid tissue. Am J Surg Pathol 1993; 17: 574-89.
29. Thiebelmant C, Bastion Y, Bergen F, et al. Mucosa associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behaviour: analysis of 108 patients. J Clin Oncol 1997; 15: 1624-30.
30. Isaacson P, Wright DH. Malignant lymphoma of mucosal associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer 1983; 52: 1410-16.